BioCentury
ARTICLE | Clinical News

Pradaxa: Additional Phase III data

July 2, 2012 7:00 AM UTC

Boehringer reported pooled data from the double-blind Phase III RE-MOBILIZE, RE-MODEL, RE-NOVATE and RE-NOVATE II trials in 10,148 patients showing that there was no significant difference between once-daily 150 or 220 mg Pradaxa and enoxaparin in the incidence of treatment-emergent ACS events (0.51% and 0.16%, respectively, vs. 0.35%). Additionally, there was no significant difference between low- and high-dose Pradaxa and enoxaparin in the incidence of MI (0.51% and 0.11%, respectively, vs. 0.35%). Data were published in Thrombosis Research. ...